检索结果-南通市图书馆

safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

2007医学前沿论坛暨第十届全国肿瘤药理与化疗学术会议

作者： chen xueqin~1 ma shenglin~2 mou hanzhou~2 feng jianguo~2 1.department of tumor,hangzhou first people’s hospital,hangzhou 310006,china 2.institute of oncology,zhejiang cancer hospital,hangzhou,310022,china

Objective:To observe the synergistic effects of hyperthrnia and cisplatin on human lung adenocarcinoma cell line ***:Cells treated with or without hyperthermia at 42℃ for 2 hours were detected cisplatin sensitivity with CCK-8 *** managed with hyperthermia at 42 ℃ for 2 hours,ciplatin 10ug/ml for 24 hours or both of two sides,inhibition ratio was detected with CCK-8 assay and flow cytometry analyzed DNA contents in every phase of cell ***: After hyperthermia,IC5o values of cell to cisplatin decreased from 9.51ug/ml to 6.07ug/***-8 assay showed hyperthermia and ciplatin had synergistic killing effects,and FCM also showed hyperthermia had significant effects on cell cycle with increase of G/G phase population and reduction of s phase *** can significantly increase the sensitivity of H 1299 cell line to cisplatin.

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2024年第4期30卷 339-347页

作者： JI Hua-feng YANG Zi-qiang HAN Jun-jun LI He-fang JIN Zhao-qing chen Wei-qing chen Fei-hua GONG mou-chun department of General surgery First People's Hospital of Hangzhou Lin'an DistrictHangzhou(311300)China

Objective To explore the anti-tumor effect of safflower yellow(sY)against hepatocellular carcinoma(HCC)and the underlying potential *** An in vitro model was established by mixing Luc-Hepa1-6 cells and CD3^(+)CD8^(+)T cells,followed by adding programmed cell death protein 1(PD-1)antibody(Anti-mPD-1)with or without *** apoptosis was detected by flow cytometry and the level of inflammatory cytokines was determined by enzyme-linked immunosorbent *** protein levels of programmed cell death 1 ligand 1(PD-L1),chemokine ligand(CCL5),C-X-C motif chemokine ligand 10(CXCL10)were measured by Western *** in situ animal model was established in mice followed by treatment with anti-mPD-1 with or without *** imaging was monitored with an AniView 100 imaging *** establish the FAK-overexpressed Luc-Hepa1-6 cells,cells were transfected with adenovirus containing pcDNA3.1-FAK for 48 *** The fluorescence intensity,apoptotic rate,release of inflammatory cytokines,and CCL5/CXCL10 secretion were dramatically facilitated by anti-mPD-1(Ps,which were extremely further enhanced by sY(Psed fluorescence intensity,elevated percentage of CD3+CD8+T cells,facilitated release of inflammatory cytokines,inactivated PD-1/PD-L1 axis,and increased CCL5/CXCL10 secretion were observed in Anti-mPD-1 treated mice(Pmarkedly enhanced by sY(Ps of sY on inhibiting tumor cell growth,facilitating apoptosis and inflammatory cytokine releasing,suppressing the PD-1/PD-L1 axis,and inducing the CCL5/CXCL10 secretion in Anti-mPD-1 treated mixture of Luc-Hepa1-6 cells and CD3+CD8+T cells were abolished by FAK overexpression(Psion sY inhibited the progression of HCC by mediating immunological tolerance through inhibiting FAK.

关键词： hepatocellular carcinoma safflower yellow Chinese medicine tumor microenvironment programmed cell death protein 1 focal adhesion kinase

synergistic effects of hyperthermia and cisplatin on human lung adenocarcinoma cell line H1299

在线全文

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical oncology 2007年第1期6卷 5-8页

作者： xueqin Ghen shenglin ma hanzhou mou jianguo feng department of tumor Hangzhou First People＇s Hospital Hangzhou 310006 China institute of oncology Zhejiang Cancer Hospital Hangzhou 310022 China

Objective: To observe the synergistic effects of hyperthernia and cisplatin on human lung adenocarcinoma cell line H1299. Methods: Cells treated with or without hyperthermia at 42 ℃ for 2 h were detected cisplatin sensitivity with CCK-8 assay. After managed with hyperthermia at 42 ℃ for 2 h, ciplatin 10 μg/mL for 24 h or both of two sides, inhibition ratio was detected with CCK-8 assay and flow cytometry analyzed DNA contents in every phase of cell proliferation. Results: After hy- perthermia, IC50 values of cell to cisplatin decreased from 9.51 μg/mL to 6.07 μg/mL. CCK-8 assay showed hyperthermia and ciplatin had synergistic killing effects, and FCM also showed hyperthermia had significant effects on cell cycle with increase soef nGs0i/tGivi1t yp ohfa Hse1 2p9o9p uclealtl iolinne a tnod c irsepdluactitnio. n of s phase population. Conclusion: Hyperthermia can significantly increase

关键词：高热顺铂协同效应肺腺癌细胞系 H1299 细胞毒性

Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第20期136卷 2397-2411页

作者： feng Jiao Jiujie Cui Deliang Fu Qi Li Zheng Wu Zan Teng Hongmei Zhang Jun Zhou Zhihong Zhang Xiaobing chen Yuhong Zhou Yixiong Li Yiping mou Renyi Qin Yongwei sun Gang Jin Yuejuan cheng Jian Wang Gang Ren Jiang Yue Guangxin Jin Xiuying Xiao Liwei Wang on behalf of Pancreatic tumor Group,society of oncology,Chinese Medical Association department of oncology State Key Laboratory of Systems Medicine for CancerShanghai Cancer InstituteRenji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China department of Pancreatic surgery Huashan HospitalFudan UniversityShanghai 200040China department of oncology Shanghai General HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200080China department of Hepatobiliary surgery The First Affiliated Hospital of Xi’an Jiao Tong UniversityXi’anShaanxi 710061China department of oncology The First Hospital of China Medical UniversityShenyangLiaoning 110801China department of Medical oncology The First Affiliated Hospital of Air Force Medical UniversityXi’anShaanxi 710032China department of Gastrointestinal oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteBeijing 100142China department of Pathology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China department of oncology The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenan 450003China department of Medical oncology Zhongshan HospitalFudan UniversityShanghai 200032China department of General surgery Xiangya HospitalCentral South UniversityChangshaHunan 410008China department of Gastrointestinal and Pancreatic surgery Zhejiang Provincial People’s HospitalAffiliated People’s HospitalHangzhou Medical CollegeHangzhouZhejiang 310014China department of Biliary-Pancreatic surgery Affiliated Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China department of Biliary-Pancreatic surgery Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China department of Hepatobiliary Pancreatic surgery Changhai HospitalNaval Medical UniversityShanghai 200433China department of Medical oncology Peking Union Medical College HospitalChinese Academy of Medical Sci

Pancreatic neuroendocrine neoplasms(pNENs)are rare and highly heterogeneous tumors originating from pluripotent stem cells with neuroendocrine differentiation in the pancreas,constituting approximately 3%of all pancreatic tumors.^([1])The global incidence of pNENs has been increasing recently,and most cases are sporadic and more common in women.^([1,2])pNENs are clinically divided into functioning and nonfunctioning tumors depending on whether the tumors are accompanied by a clinical syndrome related to specific hormone overproduction.

关键词： neoplasms neuroendocrine diagnosis

One-year status of hepatic venous pressure gradient measurement from 85 hospitals in china

在线全文

学校读者我要写书评

暂无评论

Portal Hypertension & Cirrhosis 2024年第2期3卷 116-123页

作者： Jitao Wang Ting Cui Linpeng Zhang Zhiping Yan Lei Li Jinjun chen Junhui sun Hua Xiang He Zhu Hao Wu Jiancuo Gengzang feng Zhang Wei Wu Guohong Cao Wuhua Guo Haibin shi Hui Xue Guangjun Huang Qiang Yu Meng Niu Huiling Xiang Derun Kong Wei Gou Xuefeng Luo Fuliang He Min Yuan Wei Liu Yong Wang Hongjie Hu Xiaoli Zhu Tao Yu Qinxue sun Wei Qu Ting Lu Deqiang ma Li Zhang Jun ma Jun Yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo Ding shengjuan Yao Mingsheng Huang Fang Wang Zexin Wang Yong Huang Jianan Li Hongfeng Yi Birun Huang Zhongwei Zhao Duiping feng Yanming Lei Changlong Hou Wenbo Guo shirong Liu Gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu Wenfeng Zhang shaoqi Yang Zhouchao Hu Pengfei Pang shaowu Zhuang Weidong Wang Qingliang Zhu Kunpeng Zhang chengyu Liu Dongliang Li Chao ma Hong Jiang Xingong Zhao Weixin Ren Zhiwei Wang Lei Yu Fuhuang Lin Chaoguang Yan feng Wang Lei Yu Hui Huan Wenyong shen shaofei He chengda Zhang Jinlun Bao Jiangtao Liu Jun Wu Jianbo Zhao Jian Zhang Xiaolong Qi Hebei Provincial Key Laboratory of Cirrhosis&Portal Hypertension Xingtai People's HospitalXingtaiHebeiChina Center of Portal Hypertension Department of RadiologyZhongda HospitalSchool of MedicineSoutheast UniversityNanjingJiangsuChina department of Interventional Therapy Beijing Shijitan Hospital Affiliated to Capital Medical UniversityBeijingChina department of Intervention Taiyuan Third People's HospitalTaiyuanShanxiChina department of Intervention Zhongshan Hospital Affiliated to Fudan UniversityShanghaiChina department of Interventional Medicine The First Hospital of Lanzhou UniversityLanzhouGansuChina department of Infectious Diseases Nanfang Hospital of Southern Medical UniversityGuangzhouGuangdongChina Hepatobiliary and Pancreatic Intervention Center The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiangChina Interventional Vascular surgery Hunan Provincial People's HospitalChangshaHunanChina department of Intervention Sixth People's Hospital of ShenyangShenyangLiaoningChina department of Gastroenterology West China Hospital of Sichuan UniversityChengduSichuanChina department of Intervention The Fourth People's Hospital of Qinghai ProvinceXiningQinghaiChina department of Gastroenterology Nanjing Drum Tower HospitalNanjingJiangsuChina department of Gastroenterology The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouZhejiangChina department of Radiology Shulan(Hangzhou)HospitalHangzhouZhejiangChina department of Intervention Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujianChina department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChina department of Gastroenterology The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxiChina department of Gastroenterology Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinanShandongChina department of Interventional Radiology Fifth Medical Center

Aims:surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in *** article aimed to investigate the status of hepatic venous pressure gradient measurement in china in ***:We investigated the overall status of HVPG technology in china-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online *** counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in ***:According to the survey,85 hospitals in china used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured *** average cost of HVPG measurement was 5646.8±2327.9 *** the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy ***:This survey clarified the clinical application status of HVPG in china and confirmed that some medical institutions in china have established a foundation for this *** is still necessary to continue promoting and popularizing this technology in the future.

关键词： application status hepatic vein pressure gradient questionnaire survey

CACA Guidelines for Holistic Integrative management of Breast cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Holistic Integrative oncology 2022年第1期1卷 76-126页

作者： Jiong Wu Daiming Fan Zhimin shao Binghe Xu Guosheng Ren Zefei Jiang Yongsheng Wang feng Jin Jin Zhang Qingyuan Zhang Fei ma Jinli ma Zhonghua Wang shusen Wang Xiaojia Wang shu Wang Haibo Wang Tao Wang Xiang Wang Jing Wang Jia Wang Biyun Wang Li Fu Hongyuan Li Yehui shi Lu Gan Yunjiang Liu Jian Liu Zhenzhen Liu Qiang Liu Qiang sun Wenwu cheng Keda Yu Zhongsheng Tong Xinhong Wu Chuangui song jianguo Zhang Jian Zhang Junjie Li Bin Li man Li Huiping Li Wentao Yang Hongjian Yang Benlong Yang Hong Bu Juping shen Zhenzhou shen Yiding chen Ceshi chen Da Pang Zhimin Fan Ying Zheng Xiaoli Yu Guangyu Liu Xichun Hu Yiqun Ling Jinhai Tang Yongmei Yin Cuizhi Geng Peng Yuan Yajia Gu Cai Chang Xuchen Cao Yuan sheng Yuanxi Huang Jian Huang Weijun Peng Xiaohua Zeng Yuntao Xie Ning Liao Committee of Breast cancer society,Chinese Anti-cancer Association Key Laboratory of Breast cancer in shanghai Department of Breast SurgeryFudan University Shanghai Cancer CenterShanghai Medical College of Fudan UniversityShanghaiChina department of oncology Shanghai Medical College of Fudan UniversityShanghaiChina department of Gastroenterology Beijing Chaoyang HospitalCapital Medical UniversityBeijingChina state key Laboratory of cancer Biology National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive DiseasesFourth Military Medical UniversityXi’anChina National cancer Center/cancer hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina department of Endocrine and Breast surgery The First Affliated Hospital of Chongqing Medical UniversityYuzhongChongqingChina Medicine-oncology The Affliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese People’s Liberation Army)BeijingChina Breast Disease Center Shandong Cancer HospitalJinanChina department of Breast surgery The First Affliated Hospital of China Medical UniversityShenyangChina The 3rd department of Breast cancer China Tianjin Breast Cancer PreventionTreatment and Research CenterTianjin Medical University Cancer Institute and HospitalNational Clinical Research Center of CancerTianjinChina Harbin Medical University cancer hospital HarbinChina department of Radiation oncology Fudan University Shanghai Cancer CenterShanghai Medical College of Fudan UniversityShanghaiChina sun Yat-sen University cancer Center GuangzhouChina zhejiang cancer hospital HangzhouChina Breast Center Peking University People’s HospitalBeijingChina department of Breast Center The Affliated Hospital of Qingdao UniversityShandongChina department of oncology Fifth Medical Center of Chinese PLA General HospitalBeijingChina department of Breast surgical oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Departmen

Purpose:Breast cancer is now the most common malignant tumor *** one-fourth of female cancer patients all over the world sufer from breast *** about one in six female cancer deaths worldwide is caused by breast *** terms of absolute numbers of cases and deaths,china ranks frst in the *** CACA Guidelines for Holistic Integrative management of Breast cancer were edited to help improve the diagnosis and comprehensive treatment in ***:The Grading of Recommendations Assessment,Development and Evaluation(GRADE)was used to classify evidence and ***:The CACA Guidelines for Holistic Integrative management of Breast cancer include the epidemiology of breast cancer,breast cancer screening,breast cancer diagnosis,early breast cancer treatment,advanced breast cancer treatment,follow-up,rehabilitation,and traditional Chinese medicine treatment of breast cancer ***:We to standardize the diagnosis and treatment of breast cancer in china through the formulation of the CACA Guidelines.

关键词： Epidemiology of breast cancer Breast cancer screening Breast cancer diagnosis Early breast cancer treatment Advanced breast cancer treatment Traditional Chinese medicine treatment of breast cancer

Lung-protective Ventilation in Patients with Brain Injury： A Multicenter Cross-sectional study and Questionnaire survey in china

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2016年第14期129卷 1643-1651页

作者： Xu-Ying Luo Ying-Hong Hu Xiang-Yuan Cao Yan Kang Li-Ping Liu shou-Hong Wang Rong-Guo Yu Xiang-You Yu Xia Zhang Bao-shan Li Zeng-Xiang ma Yi-Bing Weng Heng Zhang De-Chang chen Wei chen Wen-Jin chen Xiu-Mei chen Bin Du Mei-Li Duan Jin Hu Yun-feng Hoang Gui-Jun Jia Li-Hong Li Yu-Min Liang Bing-Yu Qin Xian-Dong Wang Jian Xiong Li-Mei Yan Zheng-Ping Yang chen-Ming Dong Dong-Xin Wang Qing-Yuan Zhan shuang-Lin FU Lin Zhao Qi-Bing Huang Ying-Guang Xie Xiao-Bo Huang Guo-Bin Zhang Wang-Bin Xu Yuan Xu YaLing Liu He-Ling Zhao Rong-Qing sun Ming sun Qing-Hong cheng Xin Qu Xiao-feng Yang Ming Xu Zhong-Hua shi Han chen Xuan He Yan-Lin Yang Guang-Qiang chen Xiu-Mei sun Jian-Xin Zhou department of Critical Care Medicine Beijing Tiantan Hospital Capital Medical University Beijing 100050 China department of Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China department of Critical Care Medicine General Hospital of Ningxia Medical University Yinchuan Ningxia 750004 China department of Critical Care Medicine West China Hospital Sichuan University Chengdu Sichuan 610041 China Neurological Intensive Care Unit Beijing Tiantan Hospital Capital Medical University Beijing 100050 China department of Critical Care Medicine Guangdong General Hospital Guangzhou Guangdong 510000 China surgical Intensive Care Unit Fujian Province Hospital Fuzhou Fujian 350000 China department of Critical Care Medicine First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China department of Critical Care Medicine Bethune International Peace Hospital Shijiazhuang Hebei 050000 China department of Critical Care Medicine Yuncheng Central Hospital Yuncheng Shanxi 044000 China department of Emergency and Critical Care Medicine Cangzhou People's Hospital Cangzhou Hebei 061000 China department of Critical Care Medicine Beijing Luhe Hospital Capital Medical University Beijing 101100 China department of Critical Care Medicine First Hospital of China Medical University Shenyang Liaoning 110000 China department of Critical Care Medicine Shanghai Changzheng Hospital Shanghai 200000 China department of Critical Care Medicine Beijing Shijitan Hospital Capital Medical University Beijing 100038 China department of Critical Care Medicine Xuanwu Hospital Capital Medical University Beijing 100053 China department of Critical Care Medicine Miyun County Hospital Beijing 100038 China Medical Intensive Care Unit Peking Union Medical College Hospital Beijing 101500 China department of Critical Care Medicine Beijing Friendship Hospital Capital Medical University Beijing 100050 Chin

Background： Over the years, the mechanical ventilation （MV） strategy has changed worldwide. The aim of the present study was to describe the ventilation practices, particularly lung-protective ventilation （LPV）, among brain-injured patients in china. Methods： This study was a multicenter, 1-day, cross-sectional study in 47 Intensive Care Units （ICUs） across china. Mechanically ventilated patients （18 years and older） with brain injury in a participating ICU during the time of the study, including traumatic brain injury, stroke, postoperation with intracranial tumor, hypoxic-ischemic encephalopathy, intracranial infection, and idiopathic epilepsy, were enrolled. Demographic data, primary diagnoses, indications for MV, MV modes and settings, and prognoses on the 60th day were collected. Multivariable logistic analysis was used to assess factors that might affect the use of LPV. Results： A total of 104 patients were enrolled in the present study, 87 （83.7%） of whom were identified with severe brain injury based on a Glasgow Coma scale 〈8 points. synchronized intermittent mandatory ventilation （sIMV） was the most frequent ventilator mode, accounting for 46.2% of the entire cohort. The median tidal volume was set to 8.0 ml/kg （interquartile range [IQR], 7.0-8.9 ml/kg） of the predicted body weight; 50 （48.1%） patients received LPV. The median positive end-expiratory pressure （PEEP） was set to 5 cmH20 （IQR, 5-5 cmH20）. No PEEP values were higher than 10 cmH20. Compared with partially mandatory ventilation, supportive and spontaneous ventilation practices were associated with LPV. There were no significant differences in mortality and MV duration between patients subjected to LPV and those were not. Conclusions： Among brain-injured patients in china, sIMV was the most frequent ventilation mode. Nearly one-half of the brain-injured patients received LPV. Patients under supportive and spontaneous ventilation were more likely to receive LPV.

关键词： Brain Injury Epidemiology Lung-protective Ventilation Mechanical Ventilation

Extension Protocol for the Investigation on Nutrition status and Clinical Outcome of Patients with Common cancers in china(INsCOC)study:2021 update

在线全文

学校读者我要写书评

暂无评论

Journal of Nutritional oncology 2022年第2期7卷 64-74页

作者： Hong Xia Xu Chun Hua song Liang Yu Yin Chang Wang Zhen Ming Fu Zeng Qing Guo Yuan Lin Ying Ying shi Wen Hu Yi Ba su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Fu Xiang Zhou Xin Xia song Gong Yan chen Wen Jun ma su Xia Luo Zi Hua chen Zhi Kang chen Ming Hua Cong Hu ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang chen Xiang Hua Wu Jia Xin chen Yu Fang Lan Zhou Yong Dong feng Rong shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Min Weng Qing Hua Yao Ya Yin Yu Quan Jun Lyu Hong Qiu Ming Liu Wei Li Han Ping shi The Investigation on Nutrition status and Clinical Outcome of Common cancers(INsCOC)Group department of Nutrition Daping HospitalArmy Medical University(Third Military Medical University)Chongqing 400042China department of Epidemiology College of Public HealthZhengzhou UniversityZhengzhou 450001HenanChina cancer Center of the first hospital of Jilin University Changchun 130021Jilin China cancer Center Renmin Hospital of Wuhan UniversityWuhan 430060HubeiChina department of Medical oncology Fujian Cancer HospitalFujian Medical University Cancer HospitalFuzhou 350014FujianChina department of Gastrointestinal surgery Affiliated Tumor Hospital of Guangxi Medical UniversityNanning 530021GuangxiChina department of surgery The First Affiliated Hospital of SunYat-Sen UniversityGuangzhou 510080GuangdongChina department of Clinical Nutrition West China Hospital of Sichuan UniversityChengdu 610041SichuanChina department of Gastrointestinal oncology Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerTianjin Key Laboratory of Cancer Prevention and TherapyTianjin 300060China department of Nutrition and Metabolism of oncology The First Affiliated Hospital of University of Science and Technology of ChinaAnhui Provincial Cancer HospitalHefei 230031AnhuiChina department of Clinical Nutrition The First Hospital of Hebei Medical UniversityShijiazhuang 050031HebeiChina department of Gastrointestinal surgery Institute of GastroenterologyThe First Affiliated Hospital of Kunming Medical UniversityKunming 650032YunnanChina department of Clinical Nutrition The First Affiliated Hospital of Zhejiang Chinese Medical UniversityZhejiang Provincial Hospital of Traditional Chinese MedicineHangzhou 310006ZhejiangChina department of Clinical Nutrition Chongqing General HospitalChongqing 400014China department of Colorectal and Anal surgery Huizhou Municipal Central HospitalHuizhou 516001GuangdongChina department of Radiation and Medical oncology Zhongnan Hospital of Wuhan UniversityWuhan 430071HubeiChina department of oncology Xingtai Peo

Background malnutrition is common in patients with cancer,and this adversely affects the survival and quality of life of *** society for Nutritional oncology issued a multi-center,large-scale,long-term follow-up prospective study,the Investigation on Nutrition status and Clinical Outcome of Patients with Common cancers in china(INsCOC study)since *** is an extension to the previous 2013-2020 study *** study still sought to:①address the prognostic impact of nutritional factors and quality of life on cancer patient survival;②describe the overall and cancer-specific incidence and/or distribution of malnutrition and different measurements of patient quality of *** and study design This is an observational,multi-centered,hospital-based prospective cohort *** collection will be performed at baseline(within 48 hours after patient admission),during the hospital stay and 30 days after hospital ***-up will be conducted for 1-20 years after *** primary outcome will be the all-cause mortality/overall survival,and secondary outcomes will be the length of hospital stay and costs of *** factors will include demographic characteristics,tumor characteristics,information about chronic diseases,hematological measurements(e.g.,red blood cell count,total lymphocyte counts,hemoglobin,albumin,prealbumin,creatinine,C-reactive protein,IL-6),anthropometric measurements(e.g.,height,weight,arm circumference,arm muscle circumference,triceps skinfold thickness,and waist circumference),body composition parameters,PG-sGA scores,quality of life(as indicated by the QLQ-C30 questionnaire),muscle mass(as indicated by the calf circumference),muscle strength(as indicated by the handgrip strength),muscle function(as indicated by the six-meter walking speed test)and physical status assessments(as indicated by the Karnofsky Performance status scores).This clinical study protocol was approved by local Ethics Committees of

关键词： cancer malnutrition Nutritional status Nutritional assessment survival Patient-Generated subjective Global Assessment

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

在线全文

学校读者我要写书评

暂无评论

cancer Communications 2021年第9期41卷 889-903页

作者： Yuankai shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua shi Ming Zhou Qian sun Guolei Wang Dongji chen Yongqian shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin sun mafei Kang Tianjiang ma Yimin mao Jinsheng shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang shuyang Zhu Zheng Liu Wensheng Qiu feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju chen Yuan chen Hongbing Duan manxiang Li shengming Liu Lijun ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao shumin Wang Can Wu department of Medical oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China department of oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China department of oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China department of Thoracic oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China oncology department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China department of oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China department of Thoracic surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China department of Internal Medicine-oncology/department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The second department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China department of oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine department Shanghai East HospitalShanghai 200120P.R.China The second department of Internal Medicine-oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China oncology department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China department of oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NsCLC).Methods:stageⅢB-ⅣNsCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across china were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in solid tumors(RECIsT)version 1.1 confirmed by independent radiological review committees(IRRC).secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFs),overall survival(Os),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and may 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of september 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to may 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFs,median Os,and 1-year Os rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor